Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography

• US 8,969,532 B2
• Filed: 10/03/2007
• Issued: 03/03/2015
• Est. Priority Date: 10/03/2006
• Status: Active Grant

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: DeFrees, Shawn, Kinealy, Kyle
• Primary Examiner(s): HOWARD, ZACHARY C
• Application Number:
  US11/866,969
• Publication Number:
  US 20080253992A1
• Time in Patent Office: 2,708 Days
• Field of Search: None
• US Class Current: 530/412
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 1/13 Labelling of peptides
• CPC Class Codes: C07K 1/18 Ion-exchange chromatography
• CPC Class Codes: C07K 1/20 Partition-, reverse-phase or hydrophobic interaction chromatography
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins
• CPC Class Codes: Y10S 930/09 Erythropoietin; related peptides

Abstract

The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.

Claims

1. A method of making a composition comprising a first polypeptide conjugate, said first polypeptide conjugate comprising a first number of poly(alkylene oxide) moieties covalently linked to said first polypeptide, wherein at least one of said poly(alkylene oxide) moieties is covalently linked to said first polypeptide via a glycosyl linking group, wherein said glycosyl linking group is either covalently linked to an amino acid residue of said first polypeptide or is covalently linked to a glycosyl moiety of said first polypeptide, said method comprising:

(a) contacting a mixture comprising said first polypeptide conjugate with an anion exchange medium;

(b) eluting said first polypeptide conjugate from said anion exchange medium, forming a first eluate comprising said first polypeptide conjugate;

(c) contacting said first eluate with a hydrophobic interaction chromatography (HIC) medium; and

(d) eluting said first polypeptide conjugate from said hydrophobic interaction chromatography medium,

thereby making said composition comprising said first polypeptide conjugate.

2. The method of claim 1, wherein said mixture comprises a second polypeptide conjugate, wherein said second polypeptide conjugate comprises a second number of poly(alkylene oxide) moieties covalently linked to said second polypeptide, wherein said first number and said second number are different.

3. The method of claim 2, wherein said first polypeptide and said second polypeptide have the same amino acid sequence.

4. The method of claim 1, wherein said first polypeptide conjugate comprises a first glycosylation pattern, said first glycosylation pattern comprising at least one glycan residue covalently linked to said first polypeptide, each glycan residue optionally linked to at least one of said poly(alkylene oxide) moieties.

5. The method of claim 4, wherein said mixture comprises a second polypeptide conjugate, wherein said second polypeptide conjugate comprises a second number of poly(alkylene oxide) moieties covalently linked to said second polypeptide, wherein said first number and said second number are different.

6. The method of claim 5, wherein said second polypeptide conjugate comprises a second glycosylation pattern, wherein said second glycosylation pattern differs from said first glycosylation pattern of said first polypeptide conjugate by at least one glycosyl moiety of said at least one glycan residue.

7. The method of claim 5, wherein said mixture comprises a third polypeptide conjugate comprising a third number of poly(alkylene oxide) moieties covalently linked to said third polypeptide, wherein said third polypeptide conjugate comprises a second glycosylation pattern, wherein said second glycosylation pattern differs from said first glycosylation pattern of said first polypeptide conjugate by at least one glycosyl moiety of said at least one glycan residue.

8. The method of claim 4, wherein each of said poly(alkylene oxide) moieties is covalently linked to said first polypeptide via an O-linked or N-linked glycan residue.

9. The method of claim 4, wherein said glycosylation pattern of said first polypeptide conjugate is a substantially uniform insect-specific glycosylation pattern.

10. The method of claim 1, wherein said HIC medium is selected from a butyl and a phenyl resin.

11. The method of claim 1, wherein each of said poly(alkylene oxide) moieties is a member independently selected from a poly(ethylene glycol) moiety and a polypropylene glycol) moiety.

12. The method of claim 11, wherein each of said poly(alkylene oxide) moieties has a molecular weight between about 1 kDa and about 200 kDa.

13. The method of claim 1, wherein said first polypeptide is a therapeutic polypeptide.

14. The method of claim 1, wherein said first polypeptide is a member selected from bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 7 (BMP-7), bone morphogenetic protein 15 (BMP-15), neurotrophin-3 (NT-3), von Willebrand factor (vWF) protease, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon alpha, interferon beta, interferon gamma, α

1-antitrypsin (α

-1 protease inhibitor), glucocerebrosidase, tissue-type plasminogen activator (TPA), interleukin-2 (IL-2), leptin, hirudin, urokinase, human DNase, insulin, hepatitis B surface protein (HbsAg), chimeric diphtheria toxin-IL-2, human growth hormone (hGH), human chorionic gonadotropin (hCG), thyroid peroxidase (TPO), alpha-galactosidase, alpha-L-iduronidase, beta-glucosidase, alpha-galactosidase A, acid α

-glucosidase (acid maltase), anti-thrombin III (AT III), follicle stimulating hormone (FSH), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), fibroblast growth factor 7 (FGF-7), fibroblast growth factor 21 (FGF-21), fibroblast growth factor 23 (FGF-23), Factor VII, Factor VIII, B-domain deleted Factor VIII, vWF-Factor VIII fusion protein having full-length Factor VIII, vWF-Factor VIII fusion protein having B-domain deleted Factor VIII, Factor IX, Factor X, Factor XIII, prokinetisin, extendin-4, CD4, tumor necrosis factor receptor (TNF-R), α

-CD20, P-selectin glycoprotein ligand-1 (PSGL-1), complement, transferrin, glycosylation-dependent cell adhesion molecule (GlyCAM), neural-cell adhesion molecule (N-CAM), TNF receptor-IgG Fc region fusion protein, anti-HER2 monoclonal antibody, monoclonal antibody to respiratory syncytial virus, monoclonal antibody to protein F of respiratory syncytial virus, monoclonal antibody to TNF-α

, monoclonal antibody to glycoprotein IIb/IIIa, monoclonal antibody to CD20, monoclonal antibody to VEGF-A, monoclonal antibody to PSGL-1, monoclonal antibody to CD4, monoclonal antibody to a-CD3, monoclonal antibody to EGF, monoclonal antibody to carcinoembryonic antigen (CEA) and monoclonal antibody to IL-2 receptor.

15. The method of claim 1, wherein said first polypeptide is erythropoietin (EPO).

16. The method of claim 15, wherein said EPO is covalently linked to three poly(ethylene glycol) moieties.

17. The method of claim 16, wherein at least two of said three poly(ethylene glycol) moieties are covalently linked to said EPO via an N-linked glycan.

18. The method of claim 15, wherein said EPO comprises the amino acid sequence according to SEQ ID NO:

1, said sequence optionally having at least one mutation selected from the group consisting of Arg¹³⁹ to Ala¹³⁹, Arg¹⁴³ to Ala¹⁴³ and Lys¹⁵⁴ to Ala¹⁵⁴.

19. The method of claim 1, wherein said glycosyl linking group is an intact glycosyl linking group.

20. The method of claim 19, wherein said intact glycosyl linking group is a member selected from a glucosaminyl (GlcNH) moiety, a N-acetylglucosaminyl (GlcNAc) moiety, and a sialic acid moiety.

21. The method of claim 1, further comprising:

(e) contacting said first polypeptide conjugate with a cation exchange chromatography medium and eluting said first polypeptide conjugate from the cation exchange chromatography medium.

22. The method of claim 21, wherein step (e) is performed after step (d).

23. The method of claim 1, further comprising:

contacting said first polypeptide and a modified sugar nucleotide having a glycosyl moiety covalently linked to a poly(alkylene oxide) moiety, in the presence of a glycosyltransferase under conditions sufficient for said glycosyltransferase to form a covalent bond between said glycosyl moiety and said first polypeptide, thereby forming said first polypeptide conjugate.

24. The method of claim 23, wherein said glycosyl moiety is a sialic acid moiety and said glycosyltransferase is a sialyltransferase.

25. The method of claim 23, further comprising:

recombinantly expressing said first polypeptide in an insect cell.

26. A method of isolating a first polypeptide conjugate comprising a first number of poly(alkylene oxide) moieties covalently linked to said first polypeptide, wherein at least one of said poly(alkylene oxide) moieties is attached to said first polypeptide via a glycosyl linking group, wherein said glycosyl linking group is covalently linked to an amino acid residue of said first polypeptide or is covalently linked to a glycosyl moiety of said first polypeptide, from a second polypeptide conjugate comprising a second number of poly(alkylene oxide) moieties covalently linked to said second polypeptide, wherein said first number is selected from 1 to 20 and said second number is selected from 0-20, said first number and said second number being different, said method comprising:

(a) contacting a mixture comprising said first polypeptide conjugate and said second polypeptide conjugate with an anion exchange medium;

(b) eluting said first polypeptide conjugate and said second polypeptide conjugate from said anion exchange medium, forming a first eluate comprising said first polypeptide conjugate and said second polypeptide conjugate;

(c) contacting said first eluate with a hydrophobic interaction chromatography (HIC) medium; and

(d) eluting said first polypeptide conjugate from said hydrophobic interaction chromatography medium,

thereby isolating said first polypeptide conjugate from said second polypeptide conjugate.

27. The method of claim 26, wherein each of said poly(alkylene oxide) moieties is a member independently selected from a poly(ethylene glycol) moiety and a polypropylene glycol) moiety.

28. The method of claim 27, wherein each of said poly(alkylene oxide) moieties has an independently selected molecular weight between about 1 kDa and about 200 kDa.

29. The method of claim 26, wherein said first polypeptide and said second polypeptide have the same amino acid sequence.

30. The method of claim 26, wherein said first polypeptide is a therapeutic polypeptide.

31. The method of claim 26, wherein said first polypeptide is a member selected from bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 7 (BMP-7), bone morphogenetic protein 15 (BMP-15), neurotrophin-3 (NT-3), von Willebrand factor (vWF) protease, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon alpha, interferon beta, interferon gamma, α

1-antitrypsin (α

-1 protease inhibitor), glucocerebrosidase, tissue-type plasminogen activator (TPA), interleukin-2 (IL-2), leptin, hirudin, urokinase, human DNase, insulin, hepatitis B surface protein (HbsAg), chimeric diphtheria toxin-IL-2, human growth hormone (hGH), human chorionic gonadotropin (hCG), thyroid peroxidase (TPO), alpha-galactosidase, alpha-L-iduronidase, beta-glucosidase, alpha-galactosidase A, acid α

-glucosidase (acid maltase), anti-thrombin III (AT III), follicle stimulating hormone (FSH), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), fibroblast growth factor 7 (FGF-7), fibroblast growth factor 21 (FGF-21), fibroblast growth factor 23 (FGF-23), Factor VII, Factor VIII, B-domain deleted Factor VIII, vWF-Factor VIII fusion protein having full-length Factor VIII, vWF-Factor VIII fusion protein having B-domain deleted Factor VIII, Factor IX, Factor X, Factor XIII, prokinetisin, extendin-4, CD4, tumor necrosis factor receptor (TNF-R), α

-CD20, P-selectin glycoprotein ligand-1 (PSGL-1), complement, transferrin, glycosylation-dependent cell adhesion molecule (GlyCAM), neural-cell adhesion molecule (N-CAM), TNF receptor-IgG Fc region fusion protein, anti-HER2 monoclonal antibody, monoclonal antibody to respiratory syncytial virus, monoclonal antibody to protein F of respiratory syncytial virus, monoclonal antibody to TNF-α

, monoclonal antibody to glycoprotein IIb/IIIa, monoclonal antibody to CD20, monoclonal antibody to VEGF-A, monoclonal antibody to PSGL-1, monoclonal antibody to CD4, monoclonal antibody to a-CD3, monoclonal antibody to EGF, monoclonal antibody to carcinoembryonic antigen (CEA) and monoclonal antibody to IL-2 receptor.

32. The method of claim 26, wherein said first polypeptide is erythropoietin (EPO).

33. The method of claim 32, wherein said EPO is covalently linked to three poly(ethylene glycol) moieties.

34. The method of claim 33, wherein at least two of said three poly(ethylene glycol) moieties are covalently linked to said EPO via a N-linked glycan.

35. The method of claim 32, wherein said EPO comprises the amino acid sequence according to SEQ ID NO:

1, said sequence optionally having at least one mutation selected from the group consisting of Arg¹³⁹ to Ala¹³⁹, Arg¹⁴³ to Ala¹⁴³ and Lys¹⁵⁴ to Ala¹⁵⁴.

36. The method of claim 26, wherein said HIC medium is a member selected from a butyl and a phenyl resin.

37. The method of claim 26, wherein said glycosyl linking group is an intact glycosyl linking group.

38. The method of claim 37, wherein said intact glycosyl linking group is a member selected from a glucosaminyl (GlcNH) moiety, a N-acetylglucosaminyl (GlcNAc) moiety, and a sialic acid moiety.

39. The method of claim 26, further comprising:

(e) contacting said first polypeptide conjugate with a cation exchange chromatography medium and eluting said first polypeptide conjugate from said cation exchange chromatography medium.

40. The method of claim 39, wherein step (e) is performed after step (d).

41. The method of claim 26, wherein said first polypeptide conjugate comprises a substantially uniform insect-specific glycosylation pattern.

42. The method of claim 26, further comprising:

contacting said first polypeptide with a modified sugar nucleotide having a glycosyl moiety covalently linked to a poly(alkylene oxide) moiety, in the presence of a glycosyltransferase under conditions sufficient for said glycosyltransferase to form a covalent bond between said glycosyl moiety and said first polypeptide, thereby forming said first polypeptide conjugate.

43. The method of claim 42, wherein said glycosyl moiety is a sialic acid moiety and said glycosyltransferase is a sialyltransferase.

44. The method of claim 43, further comprising:

recombinantly expressing said first polypeptide in an insect cell.

45. The method of claim 44, further comprising:

contacting said first polypeptide and a nucleotide sugar in the presence of an enzyme for which the nucleotide sugar is a substrate under conditions sufficient for said enzyme to form a covalent bond between said sugar of said nucleotide sugar and said first polypeptide, wherein said first polypeptide is a member selected from glycosylated and non-glycosylated.

46. A method of forming a composition comprising a first erythropoietin (EPO) conjugate, said first EPO conjugate comprising a first number of poly(alkylene oxide) moieties covalently linked to said EPO, wherein said EPO conjugate comprises at least one poly(alkylene oxide) moiety that is covalently linked to said EPO via a glycosyl linking group, wherein said glycosyl linking group is covalently linked to an amino acid residue of said EPO or is covalently linked to a glycosyl moiety of said EPO, said method comprising:

(a) contacting a mixture comprising said first EPO conjugate with an anion exchange medium;

(b) eluting said first EPO conjugate from said anion exchange medium, forming a first eluate comprising said first EPO conjugate;

(c) contacting said first eluate with a hydrophobic interaction chromatography (HIC) medium; and

(d) eluting said first EPO conjugate from said hydrophobic interaction chromatography medium,

thereby forming a composition comprising said first EPO conjugate.

47. The method of claim 46, wherein said mixture of step (a) comprises a second EPO conjugate having a second number of poly(alkylene oxide) moieties covalently linked to said EPO, wherein said first number and said second number are different.

48. The method of claim 47, wherein said first number is 3 and said second number is a member selected from 0, 1, 2 and 4.

49. The method of claim 47, wherein said second EPO conjugate is present in said composition at a concentration that is less than about 10%.

50. The method of claim 46, wherein said HIC medium is a member selected from a butyl and a phenyl resin.

51. The method of claim 46, wherein each of said poly(alkylene oxide) moieties is a member independently selected from a poly(ethylene glycol) moiety and a polypropylene glycol) moiety.

52. The method of claim 51, wherein each of said poly(alkylene oxide) moieties has an independently selected molecular weight between about 1 kDa and about 200 kDa.

53. The method of claim 46, wherein said first EPO conjugate comprises three poly(ethylene glycol) moieties.

54. The method of claim 53, wherein at least two of said three poly(ethylene glycol) moieties are covalently attached to said EPO via an N-linked glycan.

55. The method of claim 46, wherein said EPO comprises the amino acid sequence according to SEQ ID NO:

1, said sequence optionally having at least one mutation selected from the group consisting of Arg¹³⁹ to Ala¹³⁹, Arg¹⁴³ to Ala¹⁴³ and Lys¹⁵⁴ to Ala¹⁵⁴.

56. The method of claim 46, wherein said glycosyl linking group is an intact glycosyl linking group.

57. The method of claim 56, wherein said intact glycosyl linking group is a member selected from a glucosaminyl (GlcNH) moiety, a N-acetylglucosaminyl (GlcNAc) moiety, and a sialic acid moiety.

58. The method of claim 46, further comprising:

(e) contacting said first EPO conjugate with a cation exchange medium and eluting said first EPO conjugate from the cation exchange chromatography medium.

59. The method of claim 58, wherein step (e) is performed after step (d).

60. The method of claim 46, wherein said EPO comprises a substantially uniform insect-specific glycosylation pattern.

61. The method of claim 46, further comprising:

contacting said EPO and a modified sugar nucleotide having a glycosyl moiety covalently attached to a poly(alkylene oxide) moiety, in the presence of a glycosyltransferase under conditions sufficient for said glycosyltransferase to form a covalent bond between said glycosyl moiety and said EPO, thereby forming said first EPO conjugate.

62. The method of claim 61, wherein said glycosyl moiety is a sialic acid moiety and said glycosyltransferase is a sialyltransferase.

63. The method of claim 61, further comprising:

recombinantly expressing said EPO in an insect cell, thereby forming an insect cell-culture liquid comprising said EPO.

64. The method of claim 63, further comprising:

isolating said EPO from said insect cell-culture liquid.

65. The method of claim 61, further comprising:

contacting in a single reaction vessel said EPO and a nucleotide-N-acetylglucosamine (GlcNAc) molecule and a nucleotide galactose (Gal) molecule in the presence of a N-acetylglucosamine transferase selected from GnT1 and GnT2, and a galactosyl transferase, under conditions sufficient for said N-acetylglucosamine transferase and said galactosyl transferase to form a terminal—

GlcNAc-Gal moiety covalently linked to said EPO.